Bio-Techne (TECH) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Bio-Techne Corporation (TECH) insider buying and selling: no purchases, 4 sales
64 Form 4 Table I transactions filed with the SEC by Bio-Techne Corporation insiders between 2025-08-27 and 2026-09-30 (15-month history): 0 open-market purchases and 4 sales, plus 60 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $960k by Nusse Roeland on 2025-08-25.
Bio-Techne insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Bio-Techne insiders filed 2 sales worth $437k on the open market, and no purchases.
The biggest seller was Herr Amy E. (Director): $437k in 2 sales, the only seller.
The largest trade of the period was a sale of $320k on May 8, 2026, by Herr Amy E. (Director). Form 4 on sec.gov (0000914190-26-000092).
None of the 2 sales carries the 10b5-1 plan flag on the Form 4 (sales scheduled months ahead).
The last three months show 0 sales, against 1 in the three before. The latest sale from May 8, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Bio-Techne has more sales than 8 of the other 58, ranks 51 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with TECH's sales, largest first. The full history is in the tool above, already searched.
See all 64 TECH trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2025-08-25 | 2025-08-27 | Nusse Roeland | Director | $960k | S — Open-market saleForm 4 footnoteF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.21 to $56.33 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2025-08-25 | 2025-08-27 | Baumgartner Robert V | Director | $958k | S — Open-market saleForm 4 footnoteF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.97 to $56.34 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-05-08 | 2026-05-12 | Herr Amy E. | Director | $320k | S — Open-market sale Indirect holding, through: By significant other Form 4 footnoteF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.19 to $48.31, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-02-17 | 2026-02-19 | Herr Amy E. | Director | $117k | S — Open-market sale Indirect holding, through: By significant other Form 4 footnoteF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.091 to $59.1390, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-07-29 | 2026-07-31 | Hippel James | CFO | $3.7M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-04-22 | 2026-04-24 | Hippel James | CFO | $3.3M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-05-05 | 2026-05-07 | Hippel James | CFO | $3.2M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-07-29 | 2026-07-31 | Hippel James | CFO | $3.0M | M — Option exercise | SEC |
| 2026-05-05 | 2026-05-07 | Hippel James | CFO | $3.0M | M — Option exercise | SEC |
| 2026-07-28 | 2026-07-30 | Kelderman Kim | Chief Executive Officer | $2.1M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-04-14 | 2026-04-16 | Kelderman Kim | Chief Executive Officer | $1.9M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-07-28 | 2026-07-30 | Kelderman Kim | Chief Executive Officer | $1.7M | M — Option exercise | SEC |
| 2026-05-05 | 2026-05-07 | Kelderman Kim | Chief Executive Officer | $1.4M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-05-05 | 2026-05-07 | Kelderman Kim | Chief Executive Officer | $1.3M | M — Option exercise | SEC |
| 2026-08-15 | 2026-08-18 | Kelderman Kim | Chief Executive Officer | $783k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2025-11-03 | 2025-11-05 | Hippel James | CFO | $742k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-09-22 | 2026-09-24 | Baumgartner Robert V | Director | $403k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-09-28 | 2026-09-30 | Higgins John L | Director | $403k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-05-05 | 2026-05-07 | Bohnen Shane | SVP - General Counsel | $400k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-05-05 | 2026-05-07 | Bohnen Shane | SVP - General Counsel | $400k | M — Option exercise | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Aug 27, 2025 and Sep 30, 2026 there is not one open-market purchase of Bio-Techne Corporation: 4 sales worth $2.4M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Bio-Techne Corporation's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| M | Option exercise | 27 | $10.3M |
| F | Tax withholding (shares surrendered for taxes) | 25 | $19.6M |
| A | Grant or award | 8 | $0 |
| S | Open-market sale | 4 | $2.4M |
| Total | Everything filed in the period | 64 | $32.3M |
26 of the 64 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 15 distinct people or entities have filed Bio-Techne Corporation transactions: none bought on the open market and 3 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Nusse Roeland | Director | 2 | — | $960k (1) | 2025-08-27 |
| Baumgartner Robert V | Director | 5 | — | $958k (1) | 2026-09-24 |
| Herr Amy E. | Director | 8 | — | $437k (2) | 2026-08-18 |
| Kelderman Kim | Chief Executive Officer | 11 | — | — | 2026-08-18 |
| Hippel James | CFO | 10 | — | — | 2026-08-18 |
| Bohnen Shane | SVP - General Counsel | 8 | — | — | 2026-08-18 |
| Crouse Steven C. | President - Diag & Spatial Bi | 6 | — | — | 2026-08-18 |
| Geist William | PRESIDENT, PROTEIN SCIENCES | 4 | — | — | 2026-08-18 |
Shown here are the 8 who moved the most money, out of 15. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Aug 2025: 0 purchases and 2 sales, worth $1.9M. 12 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 2 | $1.9M |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 0 | $0 |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 1 | $117k |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 1 | $320k |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 0 | $0 |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Bio-Techne Corporation (TECH) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
None of the 4 sales in the table is flagged as scheduled (10b5-1 plan), the kind signed months ahead and executed automatically. Bio-Techne has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Sep 30, 2026, and a Form 4 arrives up to two business days after the trade.
4 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.